Lakefront Biotherapeutics revenue and financials
€26.12Change from previous close: −1.14%Absolute change: −€0.30
In the fiscal year ended December 2025, Lakefront Biotherapeutics reported revenue of €1.11B (+303.50% year over year). Net income was €320.88M, a net margin of 28.9%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +303.50%
- 2025 vs 2024
- Net income growth
- +333.15%
- 2025 vs 2024
- Net margin
- 28.9%
- 2024: 26.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 3,407 | 4,136 | 4,357 | 4,734 | — |
| Current assets | 3,079 | 3,339 | 3,862 | 4,237 | — |
| Cash and equivalents | 87.9 | 64.2 | 167 | 508 | — |
| Short-term investments | 2,910 | 3,053 | 3,518 | 3,586 | — |
| Receivables | 53.2 | 88.1 | 65.7 | 77.3 | — |
| Inventory | 22.5 | 51.2 | 74.0 | 52.9 | — |
| Net property, plant and equipment | 80.7 | 123 | 126 | 154 | — |
| Goodwill | 0.0 | 70.0 | 69.6 | 69.8 | — |
| Other intangible assets | 0.8 | 165 | 128 | 146 | — |
| Long-term investments | 46.8 | 253 | 13.6 | 0.0 | — |
| Current liabilities | 153 | 335 | 428 | 523 | — |
| Accounts payable | 32.6 | 64.2 | 135 | 133 | — |
| Total debt | 6.9 | 11.7 | 9.6 | 21.9 | — |
| Total liabilities | 171 | 1,239 | 1,562 | 2,208 | — |
| Total equity (incl. minority) | 3,236 | 2,897 | 2,796 | 2,526 | — |
| Retained earnings | 211 | -134 | -228 | -497 | — |